ESPN 54th Annual Meeting

ESPN 2022


 
COVİD-19 vaccine-related side effects among adolescents with chronic kidney conditions: A single-center experience
DEMET BALTU 1 EDA DIDEM KURT SUKUR 1 TUGBA TASTEMEL ÖZTÜRK 1 BORA GÜLHAN 1 FATIH OZALTIN 1 ALI DUZOVA 1 REZAN TOPALOGLU 1

1- DEPARTMENT OF PEDIATRIC NEPHROLOGY, FACULTY OF MEDICINE, HACETTEPE UNIVERSITY
 
Introduction:

Considering the uncontrolled pandemic there is an urgent need for studies on the safety profile of the coronavirus disease-2019 (COVID-19) vaccination in children with chronic kidney conditions. Currently in Turkey COVID-19 vaccines are in use for the adolescent population. We aimed to investigate the side-effect and safety profile of COVİD-19 vaccines available for adolescents with chronic kidney disease (CKD) at our center.

Material and methods:

The study population included patients with CKD stage 2–5, glomerular disease treated with immunosuppression, patients on dialysis, and kidney transplant recipients followed-up during the pandemic. A questionnaire including demographic and medical information, history of COVID-19 infection, vaccination status, and vaccine-related side effects was administered to the patients.

Results:

Ninety eight patients (55 girls, 43 boys) were vaccinated by CoronaVac-inactivated SARS-CoV-2 (n=16) or BNT162b2 messenger RNA (mRNA) COVİD-19 (n= 82) vaccine. The mean age was 16.90 ± 2,36 years and median follow-up 4,9 (0,5-11,03) months. There were 36 stage 2-5 CKD, 8 dialysis, and 24 transplant patients in the cohort. The most common side effects were local pain (46,9 %), fatigue (17,3 %) and fever (11,2 %). No serious side effects were observed. Median duration of the symptoms was 2 (1-30) days. The longest symptom took 30 days; as dizziness in one patient with the BNT162b2 mRNA vaccine. No renal disease flare was observed post-vaccination and 11 (11,2 %) patients experienced mild COVID-19 infection (according to NIH criteria). Although side effects with mRNA seemed more frequent than the inactivated vaccine, it was statistically insignificant (p=0,10). No significant relationship was found between frequency of side effects and age, glomerular filtration rate, immunosuppressive treatments, CKD stage, and the underlying disease.

Conclusions:

Although studies with longer follow-up are needed to evaluate the efficacy and side effects of COVID-19 vaccines, our early experience showed that vaccination is safe in the young population with CKD.